These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28741244)

  • 21. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
    Pattanaik S; Malhotra S; Sharma YP; Pandhi P
    J Cardiovasc Pharmacol; 2012 May; 59(5):479-84. PubMed ID: 22569288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis.
    Han S; Jiao J; Xu J; Zimmermann D; Actis-Goretta L; Guan L; Zhao Y; Qin L
    Sci Rep; 2016 Aug; 6():31337. PubMed ID: 27539156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
    Rifaie O; Zahran A; Nammas W
    Anadolu Kardiyol Derg; 2012 Mar; 12(2):90-6. PubMed ID: 22281786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
    Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
    Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of timing of administration on lipid-lowering efficacy of statins-meta-analysis.
    Wang C; Quan Y; Wang L; Li G
    Eur J Clin Pharmacol; 2023 Dec; 79(12):1641-1656. PubMed ID: 37776377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
    Keating AJ; Campbell KB; Guyton JR
    Ann Pharmacother; 2013 Mar; 47(3):398-404. PubMed ID: 23482733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of low-fat diet on serum lipids in premenopausal and postmenopausal women: a meta-analysis of randomized controlled trials.
    Wu L; Ma D; Walton-Moss B; He Z
    Menopause; 2014 Jan; 21(1):89-99. PubMed ID: 23736858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials.
    Li GM; Zhao J; Li B; Zhang XF; Ma JX; Ma XL; Liu J
    Autoimmun Rev; 2018 Mar; 17(3):215-225. PubMed ID: 29353098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanding options with a wider range of rosuvastatin doses.
    Olsson AG
    Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
    Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
    Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
    Leiter LA; Rosenson RS; Stein E; Reckless JP; Schulte KL; Schleman M; Miller P; Palmer M; Sosef F;
    Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.